FOSTER CITY, Calif. — Gilead Sciences, Inc. announced late Thursday that it will donate Truvada for PrEP to the U.S. Centers for Disease Control and Prevention (CDC).
This comes just a day or two after Gilead announced it would release a generic version of Truvada a year earlier than planned
The company said it will provide up to 2.4 million bottles of Truvada annually for uninsured Americans at risk for HIV. The donation, which extends up to 2030, will transition to Descovy if the drug is approved for use as PrEP. Descovy is currently in trials for use in PrEP.
“We are proud to partner with CDC to dramatically expand access to medication that can help prevent new HIV infections,” said Gregg Alton, chief patient officer of Gilead. “We believe today’s donation, combined with efforts to address the root causes of the epidemic, such as racism, violence against women, stigma, homophobia and transphobia, can play an important role in ending the HIV epidemic in the United States, particularly in parts of the country with the highest burden of disease.”
The Joe.My.God. blog, while reporting on the announcement, noted that is more complicated than that. The patent for Truvada (emtricitabine and tenofovir disoproxil fumarate) is actually owned by the federal government – which has received no royalties from Gilead.